here
Hagar, Ward,  MD

Ward Hagar

MD

Internal Medicine, Sickle Cell Disease

Adult Program Director, Comprehensive Center for Sickle Cell Disease

Request appointment Refer a patient

Clinical Specialties

Sickle cell disease, thalassemia, apheresis, gene therapy, hemoglobinopathies, iron metabolism, statistics, pain management

Certifications

Board Certification
  • Internal Medicine, Geriatric Medicine

Education

Medical School

University of Virginia, VA

Residency

University of California, Davis Medical Center, CA
(Chief Resident, Internal Medicine)

Residency

University of California, Davis Medical Center, CA (Internal Medicine)

Internship

University of California, Davis Medical Center, CA

Clinic Locations

My Work

About Me

The Hemoglobinopathy Program is an integrated pediatric and adult center with a critical pediatric-adult transition program. Dr. Hagar was recruited to direct our Adult Sickle Cell Program and provide adult hematology services for our thalassemia center. After completing both the Advanced Training in Clinic Research at UCSF and an NIH T32 clinical training program focusing on transfusional iron, he has been an investigator on numerous clinical trials involving sickle cell and thalassemia and their complications. He is actively involved in national sickle cell policy. He is a co-author of the Social Security Administration’s revision of disability criteria for sickle cell and other anemias and serves on protocol design committees for multicenter studies. He continues to work on aspects of adults with sickle cell disease, serving on the protocol design committee for multicenter studies for both pharmaceutical studies and NIH- funded trials. He has served on several National Heart, Lung, and Blood Institute and Data Safety Monitoring Committees. He manages hundreds of sickle cell patients both in the clinic, our day hospital transfusion unit, and in local hospitals, serving as the sickle cell consultant and resource for emergency departments and hospitalist groups. He has been a mentor to fellows in pediatric and medicine hem/onc programs. He is the principal investigator for a pilot study comparing genomic changes in severe sickle cell patients versus benign patients supported by Bayer Research Healthcare LLC, as well as a proposal evaluating elastase inhibitors in the treatment of acute chest syndrome.medicine-hematology/oncology programs. He is the principal investigator for a pilot study comparing genomic changes in severe sickle cell patients versus benign patients supported by Bayer Research Healthcare LLC and a proposal evaluating elastase inhibitors in the treatment of acute chest syndrome.

Selected Research and Publications:

  1. Paulukonis et al, “Defining the new face of sickle cell disease mortality using a population-based surveillance system,” [in press: Public Health Reports]
  2. Hagar, R. W. Teasing Apart Pain in Sickle Cell Disease. Eur J Haematol. 2015 Aug;95(2):101-2.
  3. Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P. (2012). "Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management." ScientificWorldJournal 2012;2012:949535.
  4. Bloch EM, Herwaldt BL, Leiby DA, Shaieb A, Herron RM, Chervenak M, Reed W, Hunter R, Ryals R, Hagar W, Xayavong MV, Slemenda SB, Pieniazek NJ, Wilkins PP, Kjemtrup AM. "The Third Described Case of Transfusion-transmitted Babesia duncani." Transfusion 2012 Jul;52(7):1517- 22.
  5. Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, Hagar RW, Howard T, Nuss R, Okam MM, Tremonti CK, Berman B, Villella A, Krishnamurti L, Lanzkron S, Castro O, Gordeuk VR, Coles WA, Peters-Lawrence M, Nichols J, Hall MK, Hildesheim M, Blackwelder WC, Baldassarre J, Casella JF; DeNOVO Investigators. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011;305(9): 893-902.
  6. Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011 Jun;153(5):655-63.
  7. Hagar, R. W., J. G. Michlitsch, et al. (2008). "Clinical differences between children and adults with pulmonary hypertension and sickle cell disease." Br J Haematol 140(1): 104-112.